API
< Back to all clusters
[HEALTH] · Greece · 3 sources

started · updated

EOPYY pharmacies face management gaps in drugs worth €2.6 billion

An audit by the Court of Audit has revealed significant deficiencies in the management of high-cost medicines within EOPYY pharmacies. The report covers 14 pharmacies during the period from 2024 through April 2025. The cost of managed drugs reached approximately €2.3 billion in 2024 and is projected at €2.6 billion for 2025, based on procurement prices before VAT and discounts.

Key findings include inadequate monitoring of stock levels and a lack of systematic internal oversight. The current information system fails to provide automated tracking for medication expiration dates or establish minimum safety stock levels. This lack of automated alerts regarding low inventory poses a risk to the continuous availability of essential medicines for patients with serious conditions, such as cancer, autoimmune diseases, and neurological disorders.

Additionally, the audit noted irregularities in procurement, including instances where new orders were placed despite existing stock being available, and cases where no consumption had been recorded for several months. These issues highlight broader difficulties in order planning and overall inventory management.

Entities

Court of Audit · EOPYY · Greece